Progress in bladder cancer monitoring bodes well for Cellmid
Published 13-DEC-2016 14:57 P.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Shares in Cellmid (ASX: CDY) surged nearly 8% on Monday after the company announced several important developments, particularly in relation to its midkine diagnostic license agreement with Pacific Edge Biotechnology.
CDY is an early stage company and historical trading activity is not indicative of future share price performances. Investors considering CDY should not base investment decisions on this data alone. It should also be borne in mind that the company is an early stage exploration group with no immediate production profile.
Pacific Edge is a listed diagnostic company based in New Zealand which has been using CDY’s midkine in their CxBladder test for the diagnosis, prognosis and disease management of bladder cancer since 2010.
Over that period CDY has received total revenues of $1.2 million, including the $92,000 in royalties due to be received for the six months to September 30, 2016.
While this has been a significant income driver for CDY, Pacific Edge’s success in 2016 relating to the provision of the CxBladder test for 10.2 million veterans enrolled in the Veteran’s Administration, as well as for military personnel at 150 US Department of Defence facilities will deliver substantial revenue growth in the future.
In addition to this development, Pacific Edge became Approved Provider to Tricare Health Plan networks in the US, which provide health care to 9.4 million beneficiaries of the US Military Health system.
This occurred in October, indicating the associated upside in income will be more apparent in the first half of calendar year 2017. Furthermore, a full year’s contribution from both initiatives in fiscal 2018 should have a positive impact on CDY’s financial performance in that year
Expanded use of CxBladder is an important long-term revenue driver
Further to these developments, CxBladder monitor has been adopted as a replacement for cystoscopy for low-risk patients monitored for recurrence of bladder cancer by the Waitemata District Health Board.
The fact that clinical results of the same test were accepted for publication in the American Journal of Urology this month suggests CDY may be able to increase its market coverage, thereby growing revenues from this product.
Looking specifically at this development, CDY’s chief executive Maria Halasz said, “Monitoring patients with bladder cancer is one of the most significant market opportunities for Pacific Edge as its non-invasive CxBladder represents a clear improvement in patient care”.
Given many patients have up to 24 visits to their urologist over a five-year period with some requiring lifelong monitoring there is the prospect of extensive growth in product usage, particularly given the fact that urologists will favour products offering high-quality performance data.
As more performance data emerges from clinical collaborations, Halasz expects a broadening use of CxBladder tests.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
